<DOC>
	<DOC>NCT01936870</DOC>
	<brief_summary>The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Drug Use Investigation for Toviaz</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Patients prescribed fesoterodine (Toviaz). There are no exclustion criteria</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Toviaz</keyword>
	<keyword>Fesoterodine</keyword>
	<keyword>Post marketing surveillance</keyword>
	<keyword>Japanese</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>OAB</keyword>
	<keyword>Good post marketing practice</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>